STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma

By rosaguerrero • May 6, 2022

Schadendorf D, Dummer R, Robert C, Ribas A, Sullivan RJ, Panella T, McKean M, Santos ES, Brill K, Polli A, Pietro AD, Ascierto PA. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. Future Oncol. 2022 Jun;18(17):2041-2051. doi: 10.2217/fon-2021-1486. Epub 2022 Mar 11. PMID: 35272485.

Tags: advanced melanoma, binimetinib; encorafenib, BRAF V600 mutations, Hematology/Oncology, immunotherapy, pembrolizumab, Publications, targeted therapy, triplet combination therapy

Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden

Williamson TJ, Garon EB, Irwin MR, Choi AK, Goldman JW, Stanton AL. Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and[...]

Mutation of SIVA, a candidate metastasis gene identified from clonally related bilateral breast cancers, promotes breast cancer cell spread in vitro and in vivo

Vermehren-Schmaedick A, Peto M, Wagoner W, Chiotti KE, Ramsey E, Wang X, Rakshe S, Minnier J, Sears R, Spellman P, Luoh SW. Mutation of SIVA,[...]

A tale of two marital stressors: Comparing proinflammatory responses to partner distress and marital conflict

Wilson SJ, Syed SU, Yang IS, Cole SW. A tale of two marital stressors: Comparing proinflammatory responses to partner distress and marital conflict. Brain Behav[...]